Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement
- PMID: 19336383
- DOI: 10.1542/peds.2008-2381
Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement
Erratum in
- Pediatrics. 2009 Jun;123(6):1611
Abstract
Description: This is an update of the 2002 US Preventive Services Task Force recommendation on screening for child and adolescent major depressive disorder.
Methods: The US Preventive Services Task Force weighed the benefits and harms of screening and treatment for major depressive disorder in children and adolescents, incorporating new evidence addressing gaps in the 2002 recommendation statement. Evidence examined included the benefits and harms of screening, the accuracy of primary care-feasible screening tests, and the benefits and risks of treating depression by using psychotherapy and/or medications in patients aged 7 to 18 years.
Recommendations: Screen adolescents (12-18 years of age) for major depressive disorder when systems are in place to ensure accurate diagnosis, psychotherapy (cognitive-behavioral or interpersonal), and follow-up (B recommendation). Evidence is insufficient to warrant a recommendation to screen children (7-11 years of age) for major depressive disorder (I statement).
Similar articles
-
Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2016 Mar 1;164(5):360-6. doi: 10.7326/M15-2957. Epub 2016 Feb 9. Ann Intern Med. 2016. PMID: 26858097
-
Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.Pediatrics. 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8. Pediatrics. 2016. PMID: 26908686
-
Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force.Pediatrics. 2009 Apr;123(4):e716-35. doi: 10.1542/peds.2008-2415. Pediatrics. 2009. PMID: 19336361 Review.
-
Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.JAMA. 2022 Oct 18;328(15):1534-1542. doi: 10.1001/jama.2022.16946. JAMA. 2022. PMID: 36219440
-
Screening for Major Depressive Disorder in Children and Adolescents: A Systematic Review for the U.S. Preventive Services Task Force.Ann Intern Med. 2016 Mar 1;164(5):342-9. doi: 10.7326/M15-2259. Epub 2016 Feb 9. Ann Intern Med. 2016. PMID: 26857836 Review.
Cited by
-
Perceived Facilitators of and Barriers to Implementation of a Decision Support Tool for Adolescent Depression and Suicidality Screening: Focus Group and Interview Study.JMIR Ment Health. 2021 Sep 15;8(9):e26035. doi: 10.2196/26035. JMIR Ment Health. 2021. PMID: 34524090 Free PMC article.
-
A pediatrician-friendly review of three common behavioral health screeners in pediatric practice: Findings and recommendations.Pediatr Investig. 2021 Mar 22;5(1):58-64. doi: 10.1002/ped4.12246. eCollection 2021 Mar. Pediatr Investig. 2021. PMID: 33778429 Free PMC article. Review.
-
Receipt of Behavioral Health Services Among US Children and Youth With Adverse Childhood Experiences or Mental Health Symptoms.JAMA Netw Open. 2021 Mar 1;4(3):e211435. doi: 10.1001/jamanetworkopen.2021.1435. JAMA Netw Open. 2021. PMID: 33720370 Free PMC article.
-
Randomized control trial testing the effectiveness of implemented depression prevention in high-risk adolescents.BMC Med. 2020 Jul 24;18(1):188. doi: 10.1186/s12916-020-01656-0. BMC Med. 2020. PMID: 32703288 Free PMC article. Clinical Trial.
-
Drivers of and Solutions for the Overuse of Antidepressant Medication in Pediatric Populations.Front Psychiatry. 2020 Feb 13;11:17. doi: 10.3389/fpsyt.2020.00017. eCollection 2020. Front Psychiatry. 2020. PMID: 32116838 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
